Researchers at Dana-Farber Cancer Institute and Boston Medical Center conducted one of the first-ever analyses of neuroendocrine tumors (NETs) at single-cell resolution. – Dana-Farber Cancer Institute

Dana-Farber Cancer Institute, made the following post on LinkedIn:

“Researchers at Dana-Farber Cancer Institute and Boston Medical Center conducted one of the first-ever analyses of neuroendocrine tumors (NETs) at single-cell resolution, unlocking new insights into this rare and often hard-to-treat cancer. The findings represent a tremendous leap forward in understanding why these tumors are largely resistant to immunotherapy and provide key insights that could lead to future treatments.”

For details click here.
Source: Dana-Farber Cancer Institute/LinkedIn

Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts provides adults and children with cancer with the best treatment available today while developing tomorrow’s cures through cutting-edge research.  Dana-Farber researchers have contributed to the development of 35 of 75 cancer drugs recently approved by the FDA for use in cancer patients. Providing advanced training in cancer treatment and research for an international faculty, the Institute conducts community-based programs in cancer prevention, detection, and control throughout New England.